Literature DB >> 31114971

Suicide journey of H. pylori through gastric carcinogenesis: the role of non-H. pylori microbiome and potential consequences for clinical practice.

Paulo Pimentel de Assumpção1, Taíssa Maíra Thomaz Araújo2, Paula Baraúna de Assumpção3, Williams Fernandes Barra2, André Salim Khayat2, Carolina Baraúna Assumpção4,5, Geraldo Ishak2,6, Diana Noronha Nunes7, Emmanuel Dias-Neto7, Luiz Gonzaga Vaz Coelho8.   

Abstract

Despite being one of the most studied cancer-related infections, the relationship between Helicobacter pylori infection and gastric adenocarcinoma (GC) remains, in some points, obscure. Based on a critical analysis of the available literature regarding stomach microbiota, we aimed to shed light to a possible new interpretation of the current understanding about the Helicobacter pylori-related GC carcinogenesis. We analyzed data from the literature on Helicobacter pylori and other potential carcinogenic pathogens, in both benignant conditions and gastric adenocarcinoma. Helicobacter pylori is the dominant microorganism in benignant conditions as non-complicated gastritis. In atrophic gastritis, metaplasia and, mainly, in gastric adenocarcinoma, a strong reduction in Helicobacter pylori abundance, and increased occurrence of other microorganisms is strongly demonstrated by metagenomic experiments. While causing peptic disease and keeping the stomach's high acidity, Helicobacter pylori infection avoids gastric infection by carcinogenic intestinal microbiota. Nevertheless, Helicobacter pylori persistence may also provoke an atrophic gastritis, a condition that causes its own decline, due to a microenvironment modification, including reduced acidity, resulting in Helicobacter pylori substitution by a cancer-prone microbiota. This new interpretation might result in a dramatic modification on clinical management of Helicobacter pylori-related gastric disease.

Entities:  

Keywords:  Carcinogenesis; Dysbiosis; Gastric cancer; Helicobacter pylori; Microbiota

Mesh:

Year:  2019        PMID: 31114971     DOI: 10.1007/s10096-019-03564-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

Review 1.  The role of non-Helicobacter pylori bacteria in the pathogenesis of gastroduodenal diseases.

Authors:  Langgeng Agung Waskito; Yudith Annisa Ayu Rezkitha; Ratha-Korn Vilaichone; Titong Sugihartono; Syifa Mustika; I Dewa Nyoman Wibawa; Yoshio Yamaoka; Muhammad Miftahussurur
Journal:  Gut Pathog       Date:  2022-05-23       Impact factor: 5.324

Review 2.  The Implication of Gastric Microbiome in the Treatment of Gastric Cancer.

Authors:  George Pappas-Gogos; Kostas Tepelenis; Fotis Fousekis; Konstantinos Katsanos; Michail Pitiakoudis; Konstantinos Vlachos
Journal:  Cancers (Basel)       Date:  2022-04-18       Impact factor: 6.575

3.  Alterations in mucosa-associated microbiota in the stomach of patients with gastric cancer.

Authors:  Yilin Deng; Xuewei Ding; Qingyuan Song; Gang Zhao; Lei Han; Bowen Ding; Xianhao Wang; Xishan Hao; Hui Li
Journal:  Cell Oncol (Dordr)       Date:  2021-03-26       Impact factor: 6.730

4.  The diffuse-type gastric cancer epidemiology enigma.

Authors:  Paulo Pimentel Assumpção; Williams Fernandes Barra; Geraldo Ishak; Luiz Gonzaga Vaz Coelho; Felipe José Fernandez Coimbra; Helano Carioca Freitas; Emmanuel Dias-Neto; M Constanza Camargo; Moyses Szklo
Journal:  BMC Gastroenterol       Date:  2020-07-13       Impact factor: 3.067

Review 5.  Hereditary gastric cancer: Three rules to reduce missed diagnoses.

Authors:  Paula Assumpção; Taíssa Araújo; André Khayat; Geraldo Ishak; Sidney Santos; Williams Barra; João Felipe Acioli; Benedito Rossi; Paulo Assumpção
Journal:  World J Gastroenterol       Date:  2020-04-07       Impact factor: 5.742

Review 6.  The role of the gastric bacterial microbiome in gastric cancer: Helicobacter pylori and beyond.

Authors:  Christian Schulz; Kerstin Schütte; Julia Mayerle; Peter Malfertheiner
Journal:  Therap Adv Gastroenterol       Date:  2019-12-18       Impact factor: 4.409

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.